BASF to purchase US biotechnology firm

Published: 23-Sep-2013
Ingredients Finance

Will pay approximately US$57m to strengthen position in enzyme growth market


BASF is to buy US biotechnology company Verenium for approximately US$62m (EUR48m).

Verenium is based in San Diego, California, and generated sales of US$57m in 2012.

The acquisition will strengthen BASF's footprint in the strategic enzyme growth market and is expected to close in the fourth quarter of 2013.

The deal has been approved by the Boards of Directors of both companies.

Under the terms of the merger agreement, Verenium shareholders will receive $4.00 per share, representing a 56% premium to the volume weighted average closing price of Verenium's common stock in the six months prior to announcement of the transaction.

  • Companies:
  • BASF Personal Care and Nutrition GmbH
See more

You may also like

Ingredients

Five key takeaways from LogiChem EU 2019

Read more
Having recently attended the LogiChem EU 2019 event in Amsterdam, the Netherlands, LLamasoft's Dr Madhav Durbha shares his insights from the chemical industry’s supply chain community

Trending Articles

  1. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  2. Rousselot Rousselot is the global leader* of collagen-based solutions for the food, health and nutrition, biomedical and pharmaceutical sectors. Working in partnership with our global customer-base, we deliver advanced ingredient solutions that enable innovation, excite today’s consumers, and contribute to public health. Rousselot is a brand of Darling Ingredients<br><br><sup>*Global Gelatin Market Insights Forecast to 2026, Calibre Research, 2020</sup>
  3. Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
  4. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams
  5. Olon Spa Olon Group is a global leader in the development and production of active pharmaceutical ingredients (APIs) for CDMO and generic markets, integrating chemical synthesis and biological processes while always embracing the highest international safety, quality, and environmental standards.

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Ingredients

Five key takeaways from LogiChem EU 2019

Having recently attended the LogiChem EU 2019 event in Amsterdam, the Netherlands, LLamasoft's Dr Madhav Durbha shares his insights from the chemical industry’s supply chain community
Ingredients

BASF completes acquisition of Chemetall

BASF has completed its acquisition of Albemarle’s global surface treatment business, Chemetall
Ingredients

BASF inaugurates new PVP production facility in Shanghai, China

Will produce PVP K30 powder used as a base for pharma excipients and cosmetics
Ingredients

Colorcon to purchase BASF’s Kollicoat IR coating system product line

The two firms will also further their cooperation to offer superior functional coatings for pharmaceutical tablets
Ingredients

BASF introduces Kollicoat MAE 100-55 for formulation of enteric film coatings

Easier handling due to dust-free material
Manufacturing

BASF establishes speciality amine production plant in Ludwigshafen

BASF’s Intermediates division develops, produces and markets more than 700 intermediates, including amines, diols, polyalcohols and acids
Ingredients

BASF to develop high purity poloxamer for Mast Therapeutics

To be used for treating specific therapeutic indications
Subscribe now